טוען...
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients rec...
שמור ב:
| הוצא לאור ב: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5310702/ https://ncbi.nlm.nih.gov/pubmed/28210165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S94337 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|